Exciting Investor Conferences Ahead for Voyager Therapeutics
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a pioneering biotechnology company focused on genetic approaches to treating neurological disorders, is gearing up for an impressive series of investor conferences. These events will serve as a platform for the company to share breakthroughs in their research and development efforts.
Key Highlights from the Upcoming Conferences
During the series of conferences, Voyager will present critical findings related to their innovative non-viral delivery platform. This platform utilizes novel receptor-binding molecules to effectively transmit various neurotherapeutics across the blood-brain barrier, a crucial aspect in the treatment of challenging neurological diseases.
Citi's Latest Biopharma Conference
The first important event is Citi's Biopharma Back to School Conference, slated for a lively fireside chat session where Voyager aims to unveil preclinical data supporting their exciting developments.
Wells Fargo Healthcare Conference
Following this, they will engage investors at the Wells Fargo Healthcare Conference, providing another opportunity to dive deep into their groundbreaking research and various treatment modalities.
Innovative Solutions for Neurological Diseases
Voyager Therapeutics is dedicated to leveraging human genetics to tackle a range of neurological issues. Their diverse pipeline showcases targeted programs for diseases like Alzheimer’s, Parkinson’s, Friedreich’s ataxia, and ALS. These innovations aim not just to manage but to potentially cure these challenging conditions.
Collaboration with Industry Leaders
Many of Voyager's initiatives are fostered through strategic partnerships with notable companies such as Alexion and AstraZeneca Rare Disease, enhancing their capabilities in developing high-penetration genetic medicines.
Comprehensive Investor Engagement
Commencing from the beginning of September, Voyager's participation will include various formats ranging from dedicated fireside chats to individual meetings. Each session is designed to provide valuable insights into their technology and address investor inquiries.
Archived Webcasts Available
For those unable to attend, webcasts of the fireside chats will be available on Voyager's website. This ensures investors can remain updated on the latest advancements and discussions surrounding their innovative therapeutics.
About Voyager Therapeutics
As a frontrunner in the biotechnology sector, Voyager Therapeutics, Inc. is committed to harnessing genetic technology to disrupt the progression of debilitating neurological disorders. Their unique TRACER™ AAV capsid discovery platform illustrates their commitment to innovation By enabling efficient delivery of genetic medicines to the brain.
Company Contacts for Further Information
For any additional inquiries, individuals can reach out to:
Trista Morrison, NACD.DC, tmorrison@vygr.com
Investors: Sarah McCabe, smccabe@jpa.com
Media: Adam Silverstein, adam@scientpr.com
Frequently Asked Questions
What is the focus of Voyager Therapeutics?
Voyager Therapeutics is focused on leveraging genetics to treat and potentially cure neurological diseases.
When will Voyager participate in investor conferences?
The investor conferences will occur early September, with several fireside chats and individual meetings.
What types of diseases are in Voyager's pipeline?
They are working on treatments for Alzheimer’s, Parkinson’s, Friedreich’s ataxia, ALS, and more.
How can investors access the conference webcasts?
Investors can watch webcasts from the fireside chats via the Investors section of Voyager’s website.
Who can I contact for more information about Voyager Therapeutics?
You can contact Trista Morrison, Sarah McCabe, or Adam Silverstein for inquiries related to Voyager Therapeutics.
